MDXG Stock Recent News

MiMedx Group, Inc. (MDXG) CEO Tim Wright on Q3 2021 Results - Earnings Call Transcript

MARIETTA, Ga., Oct. 20, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the third quarter ended September 30, 2021 after the market close on Tuesday, November 2, 2021. MIMEDX management will host a webcast and conference call to review its results on Wednesday, November 3, 2021, beginning at 8:30 am Eastern Time.

MARIETTA, Ga., Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or “the Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will host a virtual Investor Day on Tuesday, December 7, 2021 beginning at 9:00 a.m. ET. The event will focus on the Company's musculoskeletal late-stage pipeline and advanced wound care business. Further details regarding registration, presenters and format will follow.

The company released data for two drug programs and missed its goals on both.

MiMedx Group Inc (NASDAQ: MDXG) is trading significantly lower Monday after the company announced top-line results from two late-stage musculoskeletal clinical trials.  Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B clinical trial for Knee Osteoarthritis (KOA) did not meet primary endpoints, but revealed varied efficacy signals, prompting the company to plan for confirmatory efficacy studies for the KOA indication.

MiMedx Group Inc (NASDAQ: MDXG) stock dropped after announcing top-line results from two musculoskeletal trials of micronized dehydrated Human Amnion Chorion Membrane (mdHACM). Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B trial for Knee Osteoarthritis (KOA) did not meet primary endpoints.

Phase 2B Knee Osteoarthritis (KOA) Study Top-line Interim Results Demonstrate Varied Efficacy Signals between Patient Cohorts

MARIETTA, Ga., Sept. 08, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the shelf registration statement on Form S-3 on file with the Securities and Exchange Commission (SEC) has become effective. The shelf registration statement allows the Company to sell up to $350 million of various types of securities over the next three years.

MARIETTA, Ga., Sept. 07, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that Timothy R. Wright, Chief Executive Officer, Peter M. Carlson, Chief Financial Officer, and Robert B. Stein, M.D., Ph.D., Executive Vice President, Research and Development, will present at the H.C. Wainwright 23rd Annual Global Investment Conference held on September 13 - 15, 2021.

S-3 Eligibility Enabled by Accomplishment of Multiple Financial Milestones